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CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS)  
Registry Impact, Challenges, and Future Directions
Paul Mehta, MD1; D. Kevin Horton, DrPH1; Edward J. Kasarskis, MD, PhD2; Ed Tessaro3; M. Shira Eisenberg4; Susan Laird5; John Iskander, MD4
Amyotrophic lateral sclerosis (ALS), commonly known as 
Lou Gehrig’s disease, is a rapidly progressive fatal neurologic 
disease. Currently, there is no cure for ALS and the available 
treatments only extend life by an average of a few months. The 
majority of ALS patients die within 2–5 years of diagnosis, 
though survival time varies depending on disease progression 
(1,2). For approximately 10% of patients, ALS is familial, 
meaning it and has a genetic component; the remaining 90% 
have sporadic ALS, where etiology is unknown, but might be 
linked to environmental factors such as chemical exposures 
(e.g., heavy metals, pesticides) and occupational history (3).
Like many other noncommunicable conditions, ALS is a 
nonnotifiable disease in the United States; therefore, the federal 
government lacks reliable incidence and prevalence estimates 
for the United States. During October 2008, Congress passed 
the ALS Registry Act (4), directing CDC and its sister agency, 
the Agency for Toxic Substances and Disease Registry, to cre-
ate a population-based ALS registry for the United States. 
The main objectives of the National ALS Registry, which 
was launched in October 2010, are to describe the national 
incidence and prevalence of ALS; describe the demographics 
of persons living with ALS; and examine risk factors for the 
disease (4,5). During January 2017, the Registry launched the 
National ALS Biorepository, which aims to promote research 
in areas including biomarkers, genetics, and environmental 
exposures to heavy metals or organophosphates (6,7).
ALS Registry and Biorepository Methods  
and Impact
Because ALS is a nonnotifiable condition, the National ALS 
Registry uses a novel two-pronged approach for identifying 
cases in the United States (5) including searching national 
administrative databases and self-identification. The first 
approach applies a pilot-tested algorithm to large national 
databases (e.g., Medicare, Veterans Health Administration) 
to identify cases (5,8). The algorithm helps classify indi-
vidual persons as having actual, potential, or non-ALS cases 
This is another in a series of occasional MMWR reports titled 
CDC Grand Rounds. These reports are based on grand rounds 
presentations at CDC on high-profile issues in public health science, 
practice, and policy. Information about CDC Grand Rounds is 
available at https://www.cdc.gov/about/grand-rounds. 
using variables including the International Classification of 
Diseases – Ninth Revision (ICD-9) diagnostic code for ALS, 
frequency of visits to neurologists, and use of prescription drugs 
(e.g., Rilutek) (8). Patients with ALS are added directly to the 
Registry, while those considered noncases are not. Potential 
ALS patients are not added to the Registry, but are retained 
until subsequent years of administrative data are available to 
be able to make a determination (8). The second approach 
uses a secure web portal to allow persons with ALS to self-
identify (8). ALS patients answer a series of online validation 
questions (e.g., has a doctor ever diagnosed you with ALS?). 
Their responses to these questions determine whether they are 
considered actual ALS cases (8). In addition, this web portal 
approach allows ALS enrollees to take brief online risk factor 
surveys (e.g., occupational history, residential history, history 
of head trauma) that will allow scientists to learn more about 
the possible causes of ALS (8). Cases from both approaches are 
then merged and deduplicated so that cases are not counted 
multiple times (8) (Figure).
The National ALS Biorepository is part of the Registry; 
therefore, patients must enroll in the Registry to donate speci-
mens (6). The Registry conducted a multiyear pilot study to 
determine the feasibility of the Biorepository (6). A group 
of external subject matter experts provided direction and 
deemed the Biorepository to be feasible, and it was launched 
in January 2017 (6). The Biorepository has a geographically 
representative sample collection scheme, that is, not all samples 
will come from one part of country, but are distributed based 
on population density (7). There are two components of the 
Biorepository: an in-home collection and a postmortem col-
lection. The in-home collection consists of samples of blood, 
urine, and saliva from ALS patients, with an annual goal of 300 
samples. The postmortem collection, consisting of samples of 
bone, brain, spinal cord, cerebrospinal fluid, and muscle targets 
10 collections each year. The pre- and postmortem collections 
will seek to expand knowledge on ALS biomarkers, genetics, 
and ultimately, etiology. The Biorepository is unique in that 
the samples collected are not previously used or left over from 
another study. In addition, these samples will be matched with 
the Registry’s survey data as well as a Global Unique Identifier 
(for those patients who elect to have a global unique identifier 
generated), which will allow researchers to track the progress of 
patients in multiple studies securely and anonymously. When 
researchers request samples, they can receive, in addition to the 
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FIGURE. Methodology* for identification of amyotrophic lateral sclerosis (ALS), cases for inclusion in the National ALS Registry — United States, 2013
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* International Classification of Diseases – Ninth Revision (ICD-9) code, frequency of neurology visits, prescription drug use.
samples, linked risk factor data such as demographics, occupa-
tion, and military service history (7). Lastly, the National ALS 
Biorepository will facilitate ALS research on etiologies and 
possible treatments.
ALS Prevalence and Risk Factors
In 2013, the most current year for which data are available, 
the Registry identified almost 16,000 cases of ALS, correspond-
ing to a prevalence of five cases per 100,000 population in the 
United States (9). As with any surveillance system for a disease 
that is nonnotifiable, it is impossible to capture all cases of 
ALS through the Registry. For example, there are currently no 
linkages to private insurance systems such as health mainte-
nance organizations, where potential ALS patients might seek 
diagnosis or treatment.
ALS disproportionately affects whites, males, and persons 
aged 60–69 years (9); the reasons for the increased incidence 
among whites and males is unknown (9). Military veterans, 
particularly men, are at higher risk for developing ALS than 
are those who have not served (10). Veterans who served in 
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the first Gulf War were twice as likely to develop ALS as were 
veterans who served during the same period but were not 
deployed to the Gulf (11). The reason for the increased risk 
among veterans is not known, but it might be related to selec-
tive environmental exposures (9,10).
Participation by athletes in certain sports, specifically 
American football, has purportedly been associated with an 
increased risk of developing ALS; several high-profile diagnoses 
in professional football players have also brought increased 
attention to ALS (12). Currently, it is unknown if football 
players might be at a greater risk for ALS than the general popu-
lation; however, some research indicates it might be related 
to experiencing repeated concussions, or that ALS could be 
confused with a different condition such as chronic traumatic 
encephalopathy (12). More research is needed to investigate 
etiology of ALS and to learn more about the pathophysiology.
 ALS incidence is stable; however, the prevalence slowly 
continues to increase (13).  Proposed reasons for the increase 
in prevalence includes comprehensive health care that allows 
patients to live longer, and large ALS clinics that provide 
patients with neurologic and nursing care, dietary support, and 
physical therapy care in one setting (13). However, not all ALS 
patients have access to large multidisciplinary ALS clinics, and 
those living in rural areas still tend to see their local primary 
care physician or neurologist (13,14).
Challenges for Research, Drug Development, and 
Patient Care
The onset of ALS is insidious. Patients might experience 
weakness in an upper or lower limb or difficulty speaking or 
swallowing, with bulbar onset disease. No definitive blood, 
cerebrospinal fluid, or imaging biomarkers for ALS have 
been identified yet; thus, ALS is often a diagnosis of exclu-
sion, typically made after other diseases have been ruled out 
(15). As a result, approximately 9–12 months might elapse 
during the onset of new progressive weakness and a defini-
tive diagnosis. This time window, essentially one quarter of 
an ALS patient’s remaining lifespan, is a lost opportunity for 
developing drugs aimed at stopping the degeneration and 
death of motor neurons.
Researchers can measure and monitor ALS progression and 
the effectiveness of drugs in clinical trials using self-rating of 
function with the ALS Functional Rating Scale or quantitative 
measures of muscle power, including pulmonary function tests 
(e.g., percentage of forced vital capacity, maximum inspiratory 
pressure, sniff nasal pressure), measurement of walking speed, 
and isometric muscle power (16). However, disease progression 
varies widely among patients. Certain functions can remain nor-
mal including bladder and bowel control, eye movements, and 
awareness (15). Unlike other progressive neurologic conditions 
such as Alzheimer’s disease, cognition and largely memory 
remain intact for the vast majority of ALS patients; however, new 
research suggests that frontotemporal dementia may be affecting 
more ALS patients than previously thought (17).
Barriers to progress in identifying the etiology, means of 
prevention, and cure of ALS remain formidable. An estimated 
50%–70% of motor neurons are no longer functional when 
patients with clinical signs and symptoms come to medical 
attention (15). Therefore, clinical trials that enroll ALS patients 
use drugs that can only attempt to slow disease progression. 
At this time, there are no identified therapeutics that stop or 
reverse the death of these motor neurons (15). Other barriers 
include the large number of patients required for sufficiently 
powered clinical trials and the costs of trials.
Living with ALS: A Patient’s Perspective
A patient with ALS has written, “ALS patients can have a 
zeal for life rare among patients with other diseases. Shorter life 
expectancy often spurs patient with ALS to make life experi-
ences and relationships deeper. It is helpful to understand the 
concept that ‘everyone has a wheel chair,’ and that no one 
avoids life’s crises forever.”
Organizations exist with the mission to defeat ALS through 
research, and provide support for the thousands of persons liv-
ing with the disease in the United States. Such groups include 
the ALS Association, the Muscular Dystrophy Association, and 
the Les Turner ALS Foundation. However, more support for 
research is needed. Even with continued support from private 
donors, foundations, and institutions, rare diseases (those 
with <200,000 cases diagnosed nationwide)* like ALS still 
face barriers to research funding and treatment development.
The financial consequences of ALS after diagnosis can also 
be crippling, and go well beyond typical loss of income (18). 
Living with ALS becomes cost-prohibitive for a majority of 
patients (18). Some accommodations, including home con-
version; a power wheelchair; and a van with ramp, lifts, and 
tech-assist devices can cost from $100,000 to $150,000, adding 
considerable stress to families already dealing with the diagnosis 
(18). The fear that family savings, retirement, mortgages, and 
educational funds are at risk, often provokes further health 
complications (18).
Development of a strong doctor-patient alliance can bal-
ance honest, diagnostic, and prognostic communications with 
messages that promote purpose, hope, and quality of life for 
patients with ALS. After the diagnosis, there is a great need to 
counsel patients in an affirmative way to accept the reality of 
the disease. Currently, this type of family counseling is rarely 
included in the ALS multispecialty clinic setting. Much can 
* National Organization for Rare Disorders. 
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be done to help patients cope and see firsthand the optimism 
of new research, clinical trial enrollment, technology-based 
solutions, and self-determination techniques. Reluctance to 
spend time discussing these positive aspects for fear of creating 
false hope might result in a missed therapeutic opportunity.
The National ALS Registry as a Model for 21st 
Century Surveillance
Whereas understanding the epidemiology of ALS is one of 
the main objectives of the National ALS Registry, the Registry 
also conducts other vital activities to help both patients and 
researchers learn more about the disease.
The Registry funds external research to help the ALS com-
munity learn more about potential ALS etiology and risk 
factors. To date, the Registry has funded 13 research projects 
including Large-Scale Genome-Wide Association Studies of 
ALS, gene-environment interaction studies, antecedent medi-
cal conditions, and environmental risk factors for ALS.
Importantly, the Registry is used to recruit enrollees into 
clinical trials and epidemiologic studies. The Registry speeds 
up difficult and costly clinical trial recruitment time, increases 
study sample size, and helps achieve racial, ethnic, and geo-
graphic diversity. The Registry’s services are provided free to 
researchers (9). To date, the Registry has helped scientists in 
the public and private sectors recruit hundreds of patients into 
over 30 research studies.
The National ALS Registry is the first and only population-
based ALS registry for the United States that is quantifying the 
epidemiology of the disease (8). The Registry is a critical tool 
in building the evidence to describe the ALS experience in the 
United States, provide epidemiologic data and biospecimens to 
scientists, and discover the etiology and risk factors for ALS.
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